Skip to NavigationSkip to content

Johnson & Johnson

J&J raises FY outlook, Q1 beats estimates

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds.

The company now sees full year earnings of $6.53 to $6.68 a share, up from $6.43 to $6.58 a share forecast earlier. J&J also raised its full year revenue estimates to $71.2 billion to $71.9 billion, from the previously estimated $70.8 billion to $71.5 billion

Janssen slams NICE decision on Imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that it does not intend to recommend its Imbruvica (ibrutinib) to treat chronic lymphocytic leukaemia (CLL).

J&J fined $72 million in talc cancer case

A Missouri jury has ruled that Johnson & Johnson must pay $72 million to the family of an Alabama woman, who claim that her death was caused by use of the company’s baby powder, and other talcum products.

Jacqueline Fox died of ovarian cancer last year, aged 62, having used the baby powder, as well as the company’s Shower to Shower product, for some 35 years as part of her daily routine, and believing that it contributed to her cancer. Upon her death, the case was taken up by her son.

Investigation questions Xarelto trial data accuracy

Xarelto
Bayer submitted the ROCKET-AF trial for regulatory approval with the FDA and the EMA

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from a blood testing device, it has been claimed.

An investigation in the BMJ alleges that the results, drawn from analysis of data from blood testing devices that measured the effectiveness of Xarelto (rivaroxaban), could be invalid. The testing device that was used during the trial was recalled in December 2014, after being found to give falsely low test results.

Johnson & Johnson begins Ebola vaccine trial in Sierra Leone

Ebola virus

Johnson & Johnson has begun a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies, in the first study conducted of Janssen’s Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.

Trial recruitment for the EBOVAC-Salone study is underway, with the first volunteers having received their initial vaccine dose; the study will take place in Sierra Leone’s Kambia district, where some of the country’s most recent Ebola cases have been reported.<

FDA strengthens safety warning for J&J’s diabetes drug Invokana

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes medicine Invokana.

The label for Invokana (canagliflozin) has carried a warning since the drug’s launch, concerning the risk of bone fracture. Now additional clinical trial data requested by the FDA confirmed this risk, as well as a risk of decreased bone mineral density at the hip and lower spine.

Janssen sales follow J&J’s downward trend

J&J front
J&J's overall and pharma sales are down year on year

Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s pharmaceutical arm Janssen.

Janssen’s sales fell to $7.9 billion in the second quarter of 2015, a decrease of 6.6% compared to the year before, according to the health care giant’s latest financial results.

The firm says it has been hit in the last year by the effects of a negative currency impact. Excluding the net impact of acquisitions and divestments, worldwide sales increased 1.5%, domestic sales decreased 0.6% and international sales rose by 3.9%.

J&J profits down in Q3

J&J image

Johnson & Johnson has reported a 6.5% year-on-year sales increase to $17.1 billion in the third quarter of 2012, a rise due in large part to buying surgical equipment manufacturer Synthes.

But the $21.3 billion acquisition - the subject of a $241 million charge in this quarter - helped in having the opposite effect on profit, which was down 7.3% on the same period in 2011 to $2.97 billion.

This was part of a $553 million overall charge which included costs connected to the abondonment of Phase III drug bapineuzumab IV.

Pharma creates non-profit R&D organisation

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a mission to speed up the development of new medicines.

The firms involved are: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche’s Genentech and Sanofi.

The cost of R&D and a move away from blockbusters towards personalised medicines has seen manufacturers seek new models for finding and developing drugs in recent years.

J&J buys into Genmab cancer drug

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen Biotech.

Janssen will pay $55 million upfront for daratumumab and J&J Development Corporation will invest a further $80 million in 5.4 million new Genmab shares, giving it a 10.7% equity stake in the company.

The deal, when potential development, regulatory and sales milestone payments and double digit royalties are taken into account, could top $1.1 billion, Genmab says.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches